Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Drug toxicity: Drug–Drug Interaction

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multidimensional Longitudinal Assessment of Oral Mucositis Burden and Functional Impact in Head and Neck Cancer Patients Undergoing Radiotherapy or Chemoradiotherapy: A Retrospective and Exploratory Observational Study.

Cancers·2026

Same author

Exploratory Analysis of the Neutrophil-to-Lymphocyte Ratio (NLR) and Mucositis Severity in Head and Neck Cancer Patients Undergoing Radiotherapy-Based Treatment: A Retrospective Study.

Journal of clinical medicine·2026

Same author

Late peritoneal carcinomatosis from cutaneous melanoma mimicking ovarian cancer.

Melanoma research·2025

Same author

Longitudinal prediction of drug response in high-grade serous ovarian cancer organoid cultures aligning with clinical responses.

Journal of advanced research·2025

Same author

Novel De Novo <i>BRCA2</i> Variant in an Early-Onset Ovarian Cancer Reveals a Unique Tumor Evolution Pathway.

International journal of molecular sciences·2025

Same author

Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence.

British journal of haematology·2024

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Thalidomide and lenalidomide: Mechanism-based potential drug combinations.

Sonia Vallet¹, Antonio Palumbo, Noopur Raje

¹Division of Hematology and Oncology, Cancer Center, Massachusetts General Hospital, Boston, MA, USA. svallet@partners.org

Leukemia & Lymphoma

|May 3, 2008

Summary

Thalidomide and lenalidomide are effective in treating multiple myeloma by directly killing cancer cells and altering the bone marrow microenvironment. Combining these immunomodulatory drugs may improve patient outcomes.

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Related Experiment Videos

Last Updated: Jul 5, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Area of Science:

Pharmacology
Oncology
Immunology

Background:

Thalidomide and lenalidomide are established treatments for hematological cancers like multiple myeloma (MM).
These drugs exhibit anti-inflammatory, anti-angiogenic, and immunomodulatory properties.
Their efficacy stems from a dual mechanism targeting both tumor cells and the bone marrow microenvironment.

Purpose of the Study:

To review the mechanisms of action of thalidomide and lenalidomide.
To provide a rationale for combination therapy studies.
To explore strategies for improving patient outcomes and reducing side effects in multiple myeloma treatment.

Main Methods:

Literature review of thalidomide and lenalidomide.
Analysis of their dual mechanisms of action.
Evaluation of their role in potentiating anti-MM agents.

Main Results:

Thalidomide and lenalidomide exhibit direct cytotoxicity against tumor cells.
These drugs modulate the bone marrow microenvironment, impacting cancer progression.
They enhance the efficacy of conventional and novel anti-MM therapies.

Conclusions:

Thalidomide and lenalidomide offer versatile therapeutic strategies for multiple myeloma.
Combination therapies hold promise for improved efficacy and reduced toxicity.
Further research into combination studies is warranted to optimize patient care.